A new cassava starch processing plant has been commissioned in Uganda's Kamuli District, representing a significant step toward reducing the nation's reliance on imported pharmaceutical ingredients. The fifty-million-dollar facility, developed by Dei BioPharma Ltd under Dr. Matthias Magoola, will produce essential inputs like starch and glucose for drug manufacturing.
Government officials stated the project will create thousands of jobs and provide a reliable market for local cassava farmers. It is part of a broader strategy to expand agro-processing and retain more value from domestic agricultural production. During the launch, the country's leader pledged state support for the associated industrial park but advised smallholder farmers to carefully evaluate cassava's profitability before shifting their production.
The initiative aims to strengthen local pharmaceutical supply chains and lessen dependence on imports, which have been subject to global price volatility. Industry experts anticipate that the domestic production of these starch derivatives will lower manufacturing costs and ease foreign exchange pressures.
Government officials stated the project will create thousands of jobs and provide a reliable market for local cassava farmers. It is part of a broader strategy to expand agro-processing and retain more value from domestic agricultural production. During the launch, the country's leader pledged state support for the associated industrial park but advised smallholder farmers to carefully evaluate cassava's profitability before shifting their production.
The initiative aims to strengthen local pharmaceutical supply chains and lessen dependence on imports, which have been subject to global price volatility. Industry experts anticipate that the domestic production of these starch derivatives will lower manufacturing costs and ease foreign exchange pressures.
